{"transactions":[{"id":4618853,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-16T01:30:04.000Z","date":"2026-09-11","kind":"purchase","planned":false,"acquired":true,"shares":5675,"price":1.935,"value":10981.125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":15675,"source":{"system":"sec-edgar","filing":"0001193125-26-392319","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000119312526392319/ownership.xml","form_type":"4"}},{"id":781803,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-13T21:08:07.000Z","date":"2026-05-11","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment."}],"balance_after":450000,"derivative":{"exercise_price":11.95,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001193125-26-221926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526221926/ownership.xml","form_type":"4"}},{"id":781802,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-13T21:08:07.000Z","date":"2026-05-11","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock award which vests 25% ten days after the grant date, with the remainder vesting in three equal installments on the four-month, eight-month and twelve-month anniversaries of the grant date, subject to the Reporting Person's continued employment."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-221926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526221926/ownership.xml","form_type":"4"}},{"id":786436,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-08T21:00:20.000Z","date":"2026-05-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":1350,"price":5.385,"value":7269.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units."}],"balance_after":174609,"source":{"system":"sec-edgar","filing":"0001193125-26-214913","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000119312526214913/ownership.xml","form_type":"4"}},{"id":833230,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-19T20:45:46.000Z","date":"2026-03-19","kind":"exercise","planned":false,"acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the award on January 11, 2024 and vests, as to the remaining amount of the award, in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":14295,"derivative":{"exercise_price":2.65,"expiration_date":"2033-01-11","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001193125-26-116117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000119312526116117/ownership.xml","form_type":"4"}},{"id":833229,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T20:45:46.000Z","date":"2026-03-19","kind":"exercise","planned":false,"acquired":true,"shares":5500,"price":2.65,"value":14575.0,"ownership":{"direct":true},"balance_after":175959,"source":{"system":"sec-edgar","filing":"0001193125-26-116117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000119312526116117/ownership.xml","form_type":"4"}},{"id":890398,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-20T21:30:15.000Z","date":"2026-02-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":1076,"price":11.32,"value":12180.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units."}],"balance_after":170459,"source":{"system":"sec-edgar","filing":"0001193125-26-061464","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000119312526061464/ownership.xml","form_type":"4"}},{"id":939948,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-13T21:30:07.000Z","date":"2026-01-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":1826,"price":11.57,"value":21126.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units."}],"balance_after":171535,"source":{"system":"sec-edgar","filing":"0001193125-26-011796","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000119312526011796/ownership.xml","form_type":"4"}},{"id":1255310,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T22:30:07.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":12766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in\nfour (4) substantially equal annual installments on each anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through\nthe applicable vesting date."}],"balance_after":173361,"source":{"system":"sec-edgar","filing":"0000950170-25-024336","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000095017025024336/ownership.xml","form_type":"4"}},{"id":1280149,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-06T22:21:51.000Z","date":"2025-01-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":1839,"price":8.25,"value":15171.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units (\"RSUs\")."}],"balance_after":160595,"source":{"system":"sec-edgar","filing":"0000950170-25-015541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000095017025015541/ownership.xml","form_type":"4"}},{"id":1435827,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-12T20:30:03.000Z","date":"2024-08-08","kind":"exercise","planned":false,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the award on January 11, 2024 and vests, as to the remaining amount of the award, in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":19795,"derivative":{"exercise_price":2.65,"expiration_date":"2033-01-11","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0000950170-24-095487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000095017024095487/ownership.xml","form_type":"4"}},{"id":1435826,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-12T20:30:03.000Z","date":"2024-08-08","kind":"exercise","planned":false,"acquired":true,"shares":3500,"price":2.65,"value":9275.0,"ownership":{"direct":true},"balance_after":162434,"source":{"system":"sec-edgar","filing":"0000950170-24-095487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000095017024095487/ownership.xml","form_type":"4"}},{"id":1523105,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-08T20:30:23.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of RSUs. Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in four (4) substantially equal annual installments on each anniversary of the grant\ndate, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":158934,"source":{"system":"sec-edgar","filing":"0000950170-24-055774","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000095017024055774/ownership.xml","form_type":"4"}},{"id":1523104,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-08T20:30:23.000Z","date":"2024-01-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":1853,"price":4.43,"value":8208.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units (\"RSUs\")."}],"balance_after":139934,"source":{"system":"sec-edgar","filing":"0000950170-24-055774","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000095017024055774/ownership.xml","form_type":"4"}},{"id":2054686,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-13T22:29:45.000Z","date":"2023-01-11","kind":"grant","acquired":true,"shares":23295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the award on January 11, 2024 and, as to the remaining amount of the award, in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":23295,"derivative":{"exercise_price":2.65,"expiration_date":"2033-01-11","underlying":"Common Stock","underlying_shares":23295},"source":{"system":"sec-edgar","filing":"0000899243-23-001798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000089924323001798/doc4.xml","form_type":"4"}},{"id":2054685,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-13T22:29:45.000Z","date":"2023-01-11","kind":"grant","acquired":true,"shares":6656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in four (4) substantially equal annual installments on each anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":141787,"source":{"system":"sec-edgar","filing":"0000899243-23-001798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000089924323001798/doc4.xml","form_type":"4"}},{"id":2093144,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-08T02:26:03.000Z","date":"2022-12-07","kind":"purchase","acquired":true,"shares":727,"price":3.156,"value":2294.412,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $3.15 to $3.17. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote."}],"balance_after":135131,"source":{"system":"sec-edgar","filing":"0000899243-22-037965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000089924322037965/doc4.xml","form_type":"4"}},{"id":2093143,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-08T02:26:03.000Z","date":"2022-12-06","kind":"purchase","acquired":true,"shares":2025,"price":3.162,"value":6403.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $3.15 to $3.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 970 shares acquired under the Issuer's Employee Stock Purchase Plan since January 13, 2022, the date of the last Form 4 filed by the Reporting Person (the \"Reference Date\"), and (ii) 19,276 shares that were previously awarded as restricted stock on July 22, 2020 (subject to an amendment of such award on December 7, 2020) and that vested between the Reference Date and the date hereof.  Such restricted stock award was reported in the Reporting Person's Form 3 filed on September 17, 2020, and additional restricted stock awarded pursuant to the related amendment was reported in the Reporting Person's Form 4 filed on December 10, 2020."}],"balance_after":134404,"source":{"system":"sec-edgar","filing":"0000899243-22-037965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000089924322037965/doc4.xml","form_type":"4"}},{"id":2435768,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-13T22:20:42.000Z","date":"2022-01-11","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the award on January 11, 2023 and, as to the remaining amount of the award, in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":52500,"derivative":{"exercise_price":6.04,"expiration_date":"2032-01-11","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0000899243-22-001924","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000089924322001924/doc4.xml","form_type":"4"}},{"id":2435767,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-13T22:20:42.000Z","date":"2022-01-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in four (4) substantially equal annual installments on each anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":131409,"source":{"system":"sec-edgar","filing":"0000899243-22-001924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000089924322001924/doc4.xml","form_type":"4"}},{"id":2749406,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-14T13:00:41.000Z","date":"2021-04-12","kind":"grant","acquired":true,"shares":49197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the award on April 12, 2022 and, as to the remaining amount of the award, in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":49197,"derivative":{"exercise_price":6.91,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":49197},"source":{"system":"sec-edgar","filing":"0000899243-21-015711","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000089924321015711/doc4.xml","form_type":"4"}},{"id":2949886,"issuer":{"id":6733,"kind":"organization","name":"LENSAR, Inc."},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-11T01:50:08.000Z","date":"2020-12-07","kind":"grant","acquired":true,"shares":19276,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awarded to the Reporting Person on December 7, 2020 in connection with an amendment on the same date to the restricted stock awarded to him on July 22, 2020 to amend and extend the vesting schedule applicable to such award (the \"Original Award\").  In order to comply with tax laws and to recognize the Reporting Person's agreement to an extension of the overall vesting schedule of the Original Award, the Reporting Person was issued the restricted stock award, which represents 20% of the total number of shares subject to the Original Award.  The restricted stock award will vest on the same amended vesting schedule applicable to the Original Award, which amended vesting schedule provides for vesting in quarterly installments over the approximately three-year period following the amendment date."}],"balance_after":115657,"source":{"system":"sec-edgar","filing":"0000899243-20-033396","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000089924320033396/doc4.xml","form_type":"4"}},{"id":3250615,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-25T21:28:09.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested."}],"balance_after":18000,"derivative":{"exercise_price":11.13,"exercise_date":"2020-02-21","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001127602-20-007625","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220007625/form4.xml","form_type":"4"}},{"id":3264771,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-19T21:57:25.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested."}],"balance_after":31500,"derivative":{"exercise_price":11.13,"exercise_date":"2020-02-14","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001127602-20-006488","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220006488/form4.xml","form_type":"4"}},{"id":3331858,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-12-26T22:09:40.000Z","date":"2019-12-17","kind":"grant","acquired":true,"shares":127000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":127000,"derivative":{"exercise_price":3.23,"exercise_date":"2020-12-17","expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":127000},"source":{"system":"sec-edgar","filing":"0001127602-19-035849","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219035849/form4a.xml","form_type":"4/A","original_submission_date":"2019-12-19"}},{"id":3335649,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-12-19T22:36:02.000Z","date":"2019-12-17","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":165000,"derivative":{"exercise_price":3.23,"exercise_date":"2020-12-17","expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001127602-19-035544","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219035544/form4.xml","form_type":"4"}},{"id":3519796,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-05-20T20:21:51.000Z","date":"2019-05-16","kind":"exercise","acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":61000,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001127602-19-019143","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219019143/form4.xml","form_type":"4"}},{"id":3519795,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-20T20:21:51.000Z","date":"2019-05-17","kind":"sale","acquired":false,"shares":2500,"price":7.45,"value":18625.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.41 to $7.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":125176,"source":{"system":"sec-edgar","filing":"0001127602-19-019143","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219019143/form4.xml","form_type":"4"}},{"id":3519794,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-20T20:21:51.000Z","date":"2019-05-16","kind":"sale","acquired":false,"shares":7250,"price":7.72,"value":55970.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.55 to $8.03. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":127676,"source":{"system":"sec-edgar","filing":"0001127602-19-019143","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219019143/form4.xml","form_type":"4"}},{"id":3519793,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-20T20:21:51.000Z","date":"2019-05-16","kind":"exercise","acquired":true,"shares":4750,"price":1.42,"value":6745.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":134926,"source":{"system":"sec-edgar","filing":"0001127602-19-019143","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219019143/form4.xml","form_type":"4"}},{"id":3524716,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-05-16T20:29:17.000Z","date":"2019-05-15","kind":"exercise","acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":65750,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001127602-19-018740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018740/form4.xml","form_type":"4"}},{"id":3524715,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-05-16T20:29:17.000Z","date":"2019-05-14","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":70500,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001127602-19-018740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018740/form4.xml","form_type":"4"}},{"id":3524714,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-16T20:29:17.000Z","date":"2019-05-15","kind":"sale","acquired":false,"shares":7250,"price":7.92,"value":57420.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.71 to $8.04. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":130176,"source":{"system":"sec-edgar","filing":"0001127602-19-018740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018740/form4.xml","form_type":"4"}},{"id":3524713,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-16T20:29:17.000Z","date":"2019-05-15","kind":"exercise","acquired":true,"shares":4750,"price":1.42,"value":6745.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":137426,"source":{"system":"sec-edgar","filing":"0001127602-19-018740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018740/form4.xml","form_type":"4"}},{"id":3524712,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-16T20:29:17.000Z","date":"2019-05-14","kind":"sale","acquired":false,"shares":4500,"price":7.62,"value":34290.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.55 to $7.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":132676,"source":{"system":"sec-edgar","filing":"0001127602-19-018740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018740/form4.xml","form_type":"4"}},{"id":3524711,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-16T20:29:17.000Z","date":"2019-05-14","kind":"exercise","acquired":true,"shares":4500,"price":1.42,"value":6390.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":137176,"source":{"system":"sec-edgar","filing":"0001127602-19-018740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018740/form4.xml","form_type":"4"}},{"id":3530670,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-05-13T20:57:28.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":131250,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":9750},"source":{"system":"sec-edgar","filing":"0001127602-19-018347","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018347/form4.xml","form_type":"4"}},{"id":3530669,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-05-13T20:57:28.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":141000,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":9750},"source":{"system":"sec-edgar","filing":"0001127602-19-018347","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018347/form4.xml","form_type":"4"}},{"id":3530668,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-13T20:57:28.000Z","date":"2019-05-13","kind":"sale","acquired":false,"shares":9750,"price":7.76,"value":75660.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.65 to $7.89. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":132676,"source":{"system":"sec-edgar","filing":"0001127602-19-018347","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018347/form4.xml","form_type":"4"}},{"id":3530667,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-13T20:57:28.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":9750,"price":5.51,"value":53722.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":142426,"source":{"system":"sec-edgar","filing":"0001127602-19-018347","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018347/form4.xml","form_type":"4"}},{"id":3530666,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-13T20:57:28.000Z","date":"2019-05-09","kind":"sale","acquired":false,"shares":9750,"price":7.63,"value":74392.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.51 to $7.78. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":132676,"source":{"system":"sec-edgar","filing":"0001127602-19-018347","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018347/form4.xml","form_type":"4"}},{"id":3530665,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-13T20:57:28.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":9750,"price":5.51,"value":53722.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":142426,"source":{"system":"sec-edgar","filing":"0001127602-19-018347","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219018347/form4.xml","form_type":"4"}},{"id":3538466,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-05-06T20:51:03.000Z","date":"2019-05-06","kind":"exercise","acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":150750,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001127602-19-017457","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219017457/form4.xml","form_type":"4"}},{"id":3538465,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-05-06T20:51:03.000Z","date":"2019-05-02","kind":"exercise","acquired":false,"shares":7750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":159750,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":7750},"source":{"system":"sec-edgar","filing":"0001127602-19-017457","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219017457/form4.xml","form_type":"4"}},{"id":3538464,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-06T20:51:03.000Z","date":"2019-05-06","kind":"sale","acquired":false,"shares":9000,"price":7.75,"value":69750.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.43 to $7.86. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":132676,"source":{"system":"sec-edgar","filing":"0001127602-19-017457","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219017457/form4.xml","form_type":"4"}},{"id":3538463,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-06T20:51:03.000Z","date":"2019-05-06","kind":"exercise","acquired":true,"shares":9000,"price":5.51,"value":49590.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":141676,"source":{"system":"sec-edgar","filing":"0001127602-19-017457","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219017457/form4.xml","form_type":"4"}},{"id":3538462,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-06T20:51:03.000Z","date":"2019-05-02","kind":"sale","acquired":false,"shares":7750,"price":7.3,"value":56575.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.19 to $7.42. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":132676,"source":{"system":"sec-edgar","filing":"0001127602-19-017457","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219017457/form4.xml","form_type":"4"}},{"id":3538461,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-05-06T20:51:03.000Z","date":"2019-05-02","kind":"exercise","acquired":true,"shares":7750,"price":5.51,"value":42702.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":140426,"source":{"system":"sec-edgar","filing":"0001127602-19-017457","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219017457/form4.xml","form_type":"4"}},{"id":3560833,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-04-08T18:30:00.000Z","date":"2019-04-04","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":167500,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001127602-19-014988","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219014988/form4.xml","form_type":"4"}},{"id":3560832,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-04-08T18:30:00.000Z","date":"2019-04-04","kind":"sale","acquired":false,"shares":7500,"price":8.81,"value":66075.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.80 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":132676,"source":{"system":"sec-edgar","filing":"0001127602-19-014988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219014988/form4.xml","form_type":"4"}},{"id":3560831,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-04-08T18:30:00.000Z","date":"2019-04-04","kind":"exercise","acquired":true,"shares":7500,"price":5.51,"value":41325.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019."}],"balance_after":140176,"source":{"system":"sec-edgar","filing":"0001127602-19-014988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219014988/form4.xml","form_type":"4"}},{"id":3682938,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-01-30T21:10:45.000Z","date":"2019-01-28","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":7000,"derivative":{"exercise_price":5.45,"exercise_date":"2014-08-08","expiration_date":"2023-08-08","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-19-003053","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003053/form4.xml","form_type":"4"}},{"id":3682937,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-01-30T21:10:45.000Z","date":"2019-01-28","kind":"sale","acquired":false,"shares":5000,"price":9.85,"value":49250.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":128426,"source":{"system":"sec-edgar","filing":"0001127602-19-003053","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003053/form4.xml","form_type":"4"}},{"id":3682936,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-01-30T21:10:45.000Z","date":"2019-01-28","kind":"exercise","acquired":true,"shares":5000,"price":5.45,"value":27250.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":133426,"source":{"system":"sec-edgar","filing":"0001127602-19-003053","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003053/form4.xml","form_type":"4"}},{"id":3710944,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2019-01-03T21:30:09.000Z","date":"2019-01-01","kind":"tax_withholding","acquired":false,"shares":785,"price":8.07,"value":6334.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015."}],"balance_after":132676,"source":{"system":"sec-edgar","filing":"0001127602-19-000710","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219000710/form4.xml","form_type":"4"}},{"id":3722615,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-12-21T21:06:57.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":235000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":235000,"derivative":{"exercise_price":7.06,"exercise_date":"2019-12-20","expiration_date":"2028-12-20","underlying":"Common Stock","underlying_shares":235000},"source":{"system":"sec-edgar","filing":"0001127602-18-037166","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218037166/form4.xml","form_type":"4"}},{"id":3742440,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-12-06T21:30:51.000Z","date":"2018-12-04","kind":"sale","acquired":false,"shares":3922,"price":9.45,"value":37062.9,"ownership":{"direct":true},"balance_after":133461,"source":{"system":"sec-edgar","filing":"0001127602-18-035386","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218035386/form4.xml","form_type":"4"}},{"id":3753284,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-23","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":28305,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3753283,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-21","kind":"exercise","acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":31805,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3753282,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-21","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":12000,"derivative":{"exercise_price":5.45,"exercise_date":"2014-08-08","expiration_date":"2023-08-08","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3753281,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-23","kind":"sale","acquired":false,"shares":3500,"price":9.66,"value":33810.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.65 to $9.69. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3753280,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-23","kind":"exercise","acquired":true,"shares":3500,"price":3.78,"value":13230.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":140883,"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3753279,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-21","kind":"sale","acquired":false,"shares":7000,"price":9.08,"value":63560.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.21. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3753278,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-21","kind":"exercise","acquired":true,"shares":7000,"price":3.78,"value":26460.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":144383,"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3753277,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-21","kind":"sale","acquired":false,"shares":5000,"price":9.41,"value":47050.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.40 to $9.42. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3753276,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-26T21:19:46.000Z","date":"2018-11-21","kind":"exercise","acquired":true,"shares":5000,"price":5.45,"value":27250.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":142383,"source":{"system":"sec-edgar","filing":"0001127602-18-034301","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034301/form4.xml","form_type":"4"}},{"id":3755472,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-20","kind":"exercise","acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":97071,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3755471,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-20","kind":"exercise","acquired":false,"shares":4623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":38805,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":4623},"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3755470,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-19","kind":"exercise","acquired":false,"shares":75,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":43428,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":75},"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3755469,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-20","kind":"sale","acquired":false,"shares":6500,"price":8.75,"value":56875.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.75 to $8.76. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3755468,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-20","kind":"exercise","acquired":true,"shares":6500,"price":3.22,"value":20930.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":143883,"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3755467,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-20","kind":"sale","acquired":false,"shares":4623,"price":8.57,"value":39619.11,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.30 to $8.66. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3755466,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-20","kind":"exercise","acquired":true,"shares":4623,"price":3.78,"value":17474.94,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":142006,"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3755465,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-19","kind":"sale","acquired":false,"shares":75,"price":8.3,"value":622.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3755464,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-21T21:48:15.000Z","date":"2018-11-19","kind":"exercise","acquired":true,"shares":75,"price":3.78,"value":283.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":137458,"source":{"system":"sec-edgar","filing":"0001127602-18-034192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218034192/form4.xml","form_type":"4"}},{"id":3769978,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-08","kind":"exercise","acquired":false,"shares":2302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":43503,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":2302},"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3769977,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-08","kind":"exercise","acquired":false,"shares":11113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":103571,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":11113},"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3769976,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-07","kind":"exercise","acquired":false,"shares":672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":114684,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":672},"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3769975,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-08","kind":"sale","acquired":false,"shares":2302,"price":8.3,"value":19106.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3769974,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-08","kind":"exercise","acquired":true,"shares":2302,"price":3.78,"value":8701.56,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":139685,"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3769973,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-08","kind":"sale","acquired":false,"shares":11113,"price":8.09,"value":89904.17,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.00 to $8.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3769972,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-08","kind":"exercise","acquired":true,"shares":11113,"price":3.22,"value":35783.86,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":148496,"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3769971,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-07","kind":"sale","acquired":false,"shares":672,"price":8,"value":5376.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3769970,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-09T21:14:46.000Z","date":"2018-11-07","kind":"exercise","acquired":true,"shares":672,"price":3.22,"value":2163.84,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":138055,"source":{"system":"sec-edgar","filing":"0001127602-18-032645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032645/form4.xml","form_type":"4"}},{"id":3771882,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-07T21:03:32.000Z","date":"2018-11-05","kind":"exercise","acquired":false,"shares":215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":115356,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":215},"source":{"system":"sec-edgar","filing":"0001127602-18-032411","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032411/form4.xml","form_type":"4"}},{"id":3771881,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-07T21:03:32.000Z","date":"2018-11-05","kind":"sale","acquired":false,"shares":215,"price":8,"value":1720.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-032411","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032411/form4.xml","form_type":"4"}},{"id":3771880,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-07T21:03:32.000Z","date":"2018-11-05","kind":"exercise","acquired":true,"shares":215,"price":3.22,"value":692.3,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":137598,"source":{"system":"sec-edgar","filing":"0001127602-18-032411","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032411/form4.xml","form_type":"4"}},{"id":3773534,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-06T21:04:41.000Z","date":"2018-11-02","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":45805,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001127602-18-032273","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032273/form4.xml","form_type":"4"}},{"id":3773533,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-11-06T21:04:41.000Z","date":"2018-11-02","kind":"exercise","acquired":false,"shares":7356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":115571,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":7356},"source":{"system":"sec-edgar","filing":"0001127602-18-032273","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032273/form4.xml","form_type":"4"}},{"id":3773532,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-06T21:04:41.000Z","date":"2018-11-02","kind":"sale","acquired":false,"shares":3500,"price":7.96,"value":27860.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.95 to $7.96. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-032273","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032273/form4.xml","form_type":"4"}},{"id":3773531,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-06T21:04:41.000Z","date":"2018-11-02","kind":"exercise","acquired":true,"shares":3500,"price":3.78,"value":13230.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":140883,"source":{"system":"sec-edgar","filing":"0001127602-18-032273","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032273/form4.xml","form_type":"4"}},{"id":3773530,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-06T21:04:41.000Z","date":"2018-11-02","kind":"sale","acquired":false,"shares":7356,"price":7.78,"value":57229.68,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.74 to $8.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-032273","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032273/form4.xml","form_type":"4"}},{"id":3773529,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-11-06T21:04:41.000Z","date":"2018-11-02","kind":"exercise","acquired":true,"shares":7356,"price":3.22,"value":23686.32,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":144739,"source":{"system":"sec-edgar","filing":"0001127602-18-032273","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218032273/form4.xml","form_type":"4"}},{"id":3785575,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-10-23T17:34:24.000Z","date":"2018-10-19","kind":"exercise","acquired":false,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":49305,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":3150},"source":{"system":"sec-edgar","filing":"0001127602-18-030771","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218030771/form4.xml","form_type":"4"}},{"id":3785574,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-10-23T17:34:24.000Z","date":"2018-10-19","kind":"sale","acquired":false,"shares":3150,"price":7.45,"value":23467.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.45 to $7.46. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":137383,"source":{"system":"sec-edgar","filing":"0001127602-18-030771","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218030771/form4.xml","form_type":"4"}},{"id":3785573,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Common Stock","published_at":"2018-10-23T17:34:24.000Z","date":"2018-10-19","kind":"exercise","acquired":true,"shares":3150,"price":3.78,"value":11907.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":140533,"source":{"system":"sec-edgar","filing":"0001127602-18-030771","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218030771/form4.xml","form_type":"4"}},{"id":3797479,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-10-04T17:09:15.000Z","date":"2018-10-03","kind":"exercise","acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":52455,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001127602-18-029520","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218029520/form4.xml","form_type":"4"}},{"id":3797478,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-10-04T17:09:15.000Z","date":"2018-10-03","kind":"exercise","acquired":false,"shares":972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":122927,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":972},"source":{"system":"sec-edgar","filing":"0001127602-18-029520","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218029520/form4.xml","form_type":"4"}},{"id":3797477,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-10-04T17:09:15.000Z","date":"2018-10-02","kind":"exercise","acquired":false,"shares":5528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":123899,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":5528},"source":{"system":"sec-edgar","filing":"0001127602-18-029520","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218029520/form4.xml","form_type":"4"}},{"id":3797476,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"officer":true,"officer_title":"Senior Vice President and CFO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-10-04T17:09:15.000Z","date":"2018-10-02","kind":"exercise","acquired":false,"shares":3250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018."}],"balance_after":52555,"derivative":{"exercise_price":3.78,"exercise_date":"2012-07-01","expiration_date":"2021-07-01","underlying":"Common Stock","underlying_shares":3250},"source":{"system":"sec-edgar","filing":"0001127602-18-029520","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218029520/form4.xml","form_type":"4"}}],"next_cursor":"2018-10-04T17:09:15.000000Z,3797476"}